Cargando…

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomela, Katarzyna, Pietrzak, Bernadeta, Galus, Łukasz, Mackiewicz, Jacek, Schmidt, Marcin, Mackiewicz, Andrzej Adam, Kaczmarek, Mariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000540/ https://www.ncbi.nlm.nih.gov/pubmed/36899926 http://dx.doi.org/10.3390/cells12050789

Ejemplares similares

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
por: Pietrzak, Bernadeta, et al.
Publicado: (2022)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
por: Tomela, Katarzyna, et al.
Publicado: (2020)

Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells
por: Pietrzak, Bernadeta, et al.
Publicado: (2020)

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
por: Kwiatkowska-Borowczyk, Eliza, et al.
Publicado: (2018)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6
por: Czerwinska, Patrycja, et al.
Publicado: (2020)

Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients
por: Kamińska, Paula, et al.
Publicado: (2023)

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
por: Przybyla, Anna, et al.
Publicado: (2021)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Recent advances in melanoma treatment – American Society of Clinical Oncology (ASCO) 2012 perspective
por: Mackiewicz, Jacek, et al.
Publicado: (2012)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
por: Rogala, Paweł, et al.
Publicado: (2022)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer
por: Ma, Peiwen, et al.
Publicado: (2019)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Dietary modification of myeloid-derived suppressor cells (MDSC) activity in sepsis
por: Ochoa Gautier, Juan B.
Publicado: (2022)

What is new in the treatment of advanced melanoma? State of the art
por: Mackiewicz, Jacek
Publicado: (2012)

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
por: Veltman, Joris D, et al.
Publicado: (2010)

Granulocytic Myeloid-Derived Suppressor Cells (GR-MDSC) in Breast Milk (BM); GR-MDSC Accumulate in Human BM and Modulate T-Cell and Monocyte Function
por: Köstlin, Natascha, et al.
Publicado: (2018)

Analysis of sequence variants in the 3'UTR of CDKN2A gene in melanoma patients
por: Przybyła, Anna, et al.
Publicado: (2015)

AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging
por: Salminen, Antero, et al.
Publicado: (2019)

Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency
por: Salminen, Antero, et al.
Publicado: (2019)

Intravenous Immunoglobulins Promote an Expansion of Monocytic Myeloid-Derived Suppressor Cells (MDSC) in CVID Patients
por: Simón-Fuentes, Miriam, et al.
Publicado: (2022)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
por: Wiater, Katarzyna, et al.
Publicado: (2013)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
por: Rogala, Paweł, et al.
Publicado: (2022)

Independent mechanisms of T cell-suppression by subpopulations of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts
por: Raber, Patrick L, et al.
Publicado: (2013)

Myeloid-Derived Suppressor Cells (MDSC) in the Umbilical Cord Blood: Biological Significance and Possible Therapeutic Applications
por: Bizymi, Nikoleta, et al.
Publicado: (2022)

Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma
por: Jacek, Mackiewicz, et al.
Publicado: (2015)

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023)

Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy
por: Zilio, Serena, et al.
Publicado: (2016)

Motolimod, a selective TLR8 agonist induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC)
por: Rutnam, Zina J, et al.
Publicado: (2015)

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Application of a three-dimensional (3D) breast cancer model to study macrophage polarization
por: Golabek, Agata, et al.
Publicado: (2021)

Study of circulating myeloid derived suppressor cells (MDSC) in patients with breast cancer undergoing neo-adjuvant chemotherapy; interim results
por: Wesolowski, Robert, et al.
Publicado: (2013)

Expression of H(v)1 proton channels in myeloid-derived suppressor cells (MDSC) and its potential role in T cell regulation
por: Alvear-Arias, Juan J., et al.
Publicado: (2022)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines
por: Guglas, Kacper, et al.
Publicado: (2018)

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hepkiiup7r61fvkra93qvcamie